- Home
- TYGO vs ALVR Comparison
TYGO vs ALVR Comparison
Compare TYGO & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- ALVR
- Stock Information
- Founded
- TYGO 2007
- ALVR 2013
- Country
- TYGO United States
- ALVR United States
- Employees
- TYGO N/A
- ALVR N/A
- Industry
- TYGO Semiconductors
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TYGO Technology
- ALVR Health Care
- Exchange
- TYGO Nasdaq
- ALVR Nasdaq
- Market Cap
- TYGO 58.9M
- ALVR 52.2M
- IPO Year
- TYGO N/A
- ALVR 2020
- Fundamental
- Price
- TYGO $0.97
- ALVR $9.28
- Analyst Decision
- TYGO Buy
- ALVR
- Analyst Count
- TYGO 3
- ALVR 0
- Target Price
- TYGO $3.00
- ALVR N/A
- AVG Volume (30 Days)
- TYGO 321.1K
- ALVR 29.1K
- Earning Date
- TYGO 02-11-2025
- ALVR 03-14-2025
- Dividend Yield
- TYGO N/A
- ALVR N/A
- EPS Growth
- TYGO N/A
- ALVR N/A
- EPS
- TYGO N/A
- ALVR N/A
- Revenue
- TYGO $45,985,000.00
- ALVR N/A
- Revenue This Year
- TYGO N/A
- ALVR N/A
- Revenue Next Year
- TYGO $57.24
- ALVR N/A
- P/E Ratio
- TYGO N/A
- ALVR N/A
- Revenue Growth
- TYGO N/A
- ALVR N/A
- 52 Week Low
- TYGO $0.76
- ALVR $7.96
- 52 Week High
- TYGO $2.12
- ALVR $24.15
- Technical
- Relative Strength Index (RSI)
- TYGO 53.32
- ALVR 38.21
- Support Level
- TYGO $0.76
- ALVR $7.96
- Resistance Level
- TYGO $0.89
- ALVR $10.35
- Average True Range (ATR)
- TYGO 0.17
- ALVR 1.15
- MACD
- TYGO -0.00
- ALVR 0.01
- Stochastic Oscillator
- TYGO 24.37
- ALVR 33.00
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.